Search this website. You can use fund codes to locate specific funds

Tackling post-pandemic pharmaceutical challenges

A panel debate on the role of companies and investors

Last month we looked at post-pandemic pharmaceutical challenges as part of a panel session we hosted for the US Council of Institutional Investors (CII) virtual Spring 2021 conference.

Moderated by Katie Frame, our other engagers Dr Emma Berntman and Sarah Swartz were joined by Damiano de Felice, director of strategy at the Access to Medicine Foundation and Silas Holland, head of communications and external affairs at the AMR Action Fund.

The pandemic has highlighted the vulnerability of our healthcare systems and inequities in access to them. So we asked what can companies and investors do to mitigate these issues? What did we learn along the way in the race for the vaccine? And what has the pandemic shown in terms of links between the sustainability agenda and human health?

We take a global approach to engagement with companies so our panel applied an international lens to looking at these challenges, as well as wider issues such as antimicrobial resistance and equitable vaccine distribution. Inviting questions from the audience, make sure you catch up with this session to hear why companies and investors need to step up to tackle pharmaceutical challenges in a post-pandemic world.

Watch the recording in full below or click to jump to a section.

Opening remarks – 01:33

Stimulating greater investment into R&D – 26:58

Beyond Pharma – other actors tackling AMR – 33:32

Contributors of AMR – 42:06

Equitable vaccine distribution – 51:01

Closing remarks – 57:32

Related Insights

Votes for change
This year we saw a number of companies offering shareholders a vote on their climate transition plans, including some in the oil and gas, construction, aviation, and consumer goods sectors.
Salary or sick leave – the impossible choice
In the United States, the lack of national paid family and medical leave policies underpins many difficult, often impossible, choices faced by disproportionately impacted worker populations.
Siemens Energy case study
Siemens Energy is addressing the challenges of the climate transition by setting science-based emissions reduction targets.
A watershed for climate change stewardship?
Mainstream sentiment has shifted, and the momentum is with investors calling for faster action on climate change.
Abate and switch: steel seeks low carbon solutions
Steel is considered a hard-to-abate sector, but national net-zero commitments and pressure from customers mean that solutions must be found to help drive down emissions.
Nature’s larder – why food producers must safeguard biodiversity
As many of the risks associated with the decline of nature are concentrated in the agricultural supply chain, it is imperative that companies develop a comprehensive understanding of how biodiversity underpins their business model.

EOS Client Service and Business Development

Amy D’Eugenio,
Head of Client Service and Business Development, EOS